These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3969217)

  • 1. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
    Figà-Talamanca L; Gualandi C; Di Meo L; Di Battista G; Neri G; Lo Russo F
    Neurology; 1985 Feb; 35(2):258-61. PubMed ID: 3969217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional hyperthermia due to central dopaminergic impairment.
    Di Rosa AE; Morgante L; Coraci MA; Crisafulli A; Cacciola G; Di Stefano G; Meduri M; Di Perri R
    Funct Neurol; 1988; 3(2):211-5. PubMed ID: 2900182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of neuroleptic malignant syndrome.
    Lazarus A
    Psychiatr Dev; 1986; 4(1):19-30. PubMed ID: 3703852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period.
    Mizuta E; Yamasaki S; Nakatake M; Kuno S
    Neurology; 1993 May; 43(5):1048-9. PubMed ID: 7605396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis.
    Harris M; Nora L; Tanner CM
    Clin Neuropharmacol; 1987 Apr; 10(2):186-9. PubMed ID: 3503673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of parkinsonism.
    Calne DB; Teychenne PF; Pfeiffer RF
    Adv Exp Med Biol; 1977; 90():49-61. PubMed ID: 930750
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical management of neuroleptic malignant syndrome.
    Susman VL
    Psychiatr Q; 2001; 72(4):325-36. PubMed ID: 11525080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for parkinsonism.
    Med Lett Drugs Ther; 1986 Jun; 28(716):62-4. PubMed ID: 3713639
    [No Abstract]   [Full Text] [Related]  

  • 13. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
    Hely MA; Morris JG; Reid WG; O'Sullivan DJ; Williamson PM; Rail D; Broe GA; Margrie S
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):903-10. PubMed ID: 8057111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
    Yahr MD; Clough CG; Bergmann KJ
    Lancet; 1982 Sep; 2(8300):709-10. PubMed ID: 6126641
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease, depression, and the on-off phenomenon.
    Friedenberg DL; Cummings JL
    Psychosomatics; 1989; 30(1):94-9. PubMed ID: 2913602
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 19. Drugs for parkinsonism.
    Med Lett Drugs Ther; 1988 Dec; 30(781):113-6. PubMed ID: 3143051
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of neuroleptic malignant syndrome--a series of eight cases.
    Kurien T; Rajeev KK; Abraham OC; Archana S; Cherian AM
    J Assoc Physicians India; 1993 Feb; 41(2):91-3. PubMed ID: 8101521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.